CVS Health Corporation

CVS · Healthcare

$97.60

Markedsværdi: 124.83B USDUdbytteafkast: +2.83%
AdvancedEr det et godt tidspunkt at købe CVS Health Corporation? Spørg Copenvest AIFå et Advanced AI-bud på timing, risiko og hvad tracked investorer gør.Spørg Copenvest AI

Indlæser diagram…

Nyheder

Seneste overskrifter for denne aktie

Zacks Investment Research4. sep. 2026, 15.30

CVS Health (CVS) Up 1% Since Last Earnings Report: Can It Continue?

CVS Health reported strong Q2 2026 results with adjusted EPS of $2.58 (up 42.5% YoY) and revenues of $106.10 billion (up 7.3%), beating consensus estimates. The company raised full-year 2026 guidance for earnings and revenues. However, estimates have trended downward over the past month with a -6.08% consensus shift, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns.

Zacks Investment Research2. sep. 2026, 12.39

Here's How CVS' Improving Balance Sheet Supports Deleveraging

CVS Health generated $10.6B in YTD operating cash flow and raised its full-year outlook to at least $11.5B, ending Q2 with $2.7B in cash. The company maintains a leverage ratio of 3.5x and expects improvement as it prioritizes balance-sheet strengthening over share buybacks in 2026-2027. Peers Align Technology and Cardinal Health also demonstrate strong liquidity positions with active capital deployment strategies.

Zacks Investment Research2. sep. 2026, 10.20

Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?

The iShares U.S. Healthcare Providers ETF (IHF) is a passively managed fund launched in 2006 that tracks the Dow Jones U.S. Select HealthCare Providers Index. With $1.25 billion in assets, a competitive 0.37% expense ratio, and a Zacks ETF Rank of 2 (Buy), it offers diversified exposure to healthcare providers. Year-to-date performance is up 20.18%, with a medium risk profile (beta of 0.72). Top holdings include UnitedHealth Group (20.61%), CVS Health, and Elevance Health.

The Motley Fool1. sep. 2026, 15.32

Why CVS Stock Rallied Tuesday Morning

CVS Health stock rallied 3.4-3.7% on Tuesday following bullish commentary from Jefferies analyst Brian Tanquilut, who affirmed a buy rating with a $120 price target (28% upside). The analyst highlighted strong management guidance suggesting 2027 EPS of at least $8.44, upcoming share buybacks, and Aetna's successful turnaround with over $2 billion in year-over-year operating income growth. CVS has beaten expectations for four consecutive quarters and raised full-year guidance to $8.00 adjusted EPS (19% growth).

Zacks Investment Research31. aug. 2026, 13.24

CVS vs. UNH: Which Health Insurance Stock Has More Upside Now?

UnitedHealth Group (UNH) emerges as the stronger investment choice compared to CVS Health (CVS), driven by improving results across UnitedHealthcare and Optum divisions, strong operating cash flows, and more attractive valuation. While CVS shows progress with Aetna margin recovery and pharmacy momentum, it faces 2027 headwinds from Caremark's 340B business challenges and expected membership decline. UNH trades at a 35% discount to its historical valuation multiple and has delivered stronger six-month returns.